Development of Bivalent mRNA Vaccines against SARS-CoV-2 Varinats_Company News_News_AIM Bio

NEWS

Home > News > Company News >

Development of Bivalent mRNA Vaccines against SARS-CoV-2 Varinats

2022-10-27 Source:

Previous：EV71-CA16 BIVALENT HFMD VACCINE CANDIDATE OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Next：FREEZE-DRIED HUMAN RABIES VACCINE CANDIDATE (SERUM-FREE VERO CELL) OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION